Publicador de contenidos

Investigación e Innovación Programas
Investigación, Resistencia antimicrobiana

Microbiological strategies for the treatment of pulmonary infections caused by Mycobacterium avium complex and Mycobacterium abscessus

Foto: Canva
Duración
01/01/2023 - 31/12/2025
Coordinador
Griselda Tudo & Julian Gonzalez Martin
Financiadores
Grant PI22/00536

Objectives

  1. Implement a personalized antibiogram adapted to clinical isolates of Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) in patients with chronic lung disease and infection by these species
  2. Determine the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of new/unusual antibiotics in M.avium (MAV) and MAB
  3. Determine the MIC/MCB of combinations of two new/unusual drugs and one reference in MAV and MAB
  4. Determine the MIC/CMB of the three-drugs combinations in MAV and MAB using the microdilution method and time-kill curves
  5. Analyse the biofilm production and determine the MIBC/MBEC of the three-drugs combinations in MAV and MAB 
  6. Characterize the clonal relationship in MAC and MAB isolates.

 

Methodology

MAC and MAB isolates from collection and MAC/MAB strains isolated from patients with chronic lung disease will be studied. The microdilution method will be used to design the personalised antibiogram and to study the MIC/MBC of antibiotics individually, and in two-drugs and three-drugs combinations. The three-drugs combinations will also be studied by the time-kill curves method. Biofilm production will be evaluated with the crystal violet method. The CMEB/CMIB will be determined after to treat the biofilm with the best three-drugs combinations from objective 4. Massive sequencing will be performed with the Illumina NextSeq system platform and the Fourier transform infrared spectrometry with the IR Biotyper equipment (Bruker).

Total funding

75,020 EUR

 

Nuestro equipo

Coordinadores

Equipo de ISGlobal

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

GAMA

Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

ICARIA

Improving Care through Azithromycin Research for Infants in Africa

PreFIT

Predicting the Future: Incipient Tuberculosis

ANTICOV

Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring

END-VOC

ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)

TwinAir

Digital Twins Enabled Indoor Air Quality Management for Healthy Living

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

Hepatitis C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias